{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:39:56Z","timestamp":1782362396794,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T00:00:00Z","timestamp":1326931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kaohsiung Municipal Hsiao-Kang Hospital","award":["KMHK-95-044"],"award-info":[{"award-number":["KMHK-95-044"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Positive serum antinuclear antibody (ANA) is not infrequent in chronic hepatitis C virus (HCV)\u2010infected patients. This prospective study evaluated the impact of ANA on the response to and safety of peginterferon\/ribavirin combination therapy for chronic hepatitis C patients in clinical practice. We enrolled 243 consecutive patients who were treated with a 24\u2010week regimen of peginterferon\u2010\u03b1 plus ribavirin, with a 24\u2010week follow\u2010up period. ANA titer was determined before antiviral treatment. The primary end\u2010point was sustained virological response (SVR), defined as HCV RNA &lt;50\u2009IU\/mL throughout the follow\u2010up period. Overall, 187 (77.0%) patients experienced a SVR. In the 105\u2010patient HCV genotype non\u20101 group, patients with ANA titer \u22651:80 had a significantly lower SVR rate than those with ANA titer &lt;1:80 (67.7% vs. 95.8%, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.013). In contrast, in the 138\u2010patient HCV genotype 1 group, the SVR rate did not differ between patients with and without ANA titer \u22651:80. Multivariate regressive analyses showed that ANA \u22651:80, age and HCV RNA levels were independent factors associated with SVR in HCV genotype non\u20101 patients; whereas HCV RNA levels and hepatic fibrosis were prognostic predictors of SVR in HCV genotype 1 patients. The frequencies of adverse events were similar between patients with and without ANA seropositivity. Peginterferon\/ribavirin combination therapy is effective and safe in ANA\u2010positive chronic hepatitis C patients. A\u2009high ANA titer was a negative prognostic factor for treatment response in HCV genotype non\u20101 patients.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.kjms.2011.10.031","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T06:52:22Z","timestamp":1327387942000},"page":"86-93","source":"Crossref","is-referenced-by-count":13,"title":["Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients"],"prefix":"10.1002","volume":"28","author":[{"given":"Ming\u2010Yen","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Po","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee\u2010Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan\u2010Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai\u2010Jen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu\u2010Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn\u2010Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming\u2010Yuh","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang\u2010Yen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming\u2010Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(97)80005-4"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210302"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46651995000500012"},{"key":"e_1_2_7_6_2","first-page":"417","article-title":"A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases","volume":"44","author":"Bayraktar Y.","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00530.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260305"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/427285"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/379018"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-4"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(99)80094-8"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200001000-00005"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.046276"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.05.003"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.04.003"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/135965350501000111","article-title":"Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon\u2010alpha plus ribavirin combination therapy","volume":"10","author":"Chuang W.L.","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/498244"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102558"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840010511"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.38.7.801"},{"key":"e_1_2_7_23_2","first-page":"518","article-title":"Malignant pheochromocytoma associated with Jaccoud's\u2010type arthropathy, Raynaud's phenomenon, positive antinuclear antibody and rheumatoid factor","volume":"10","author":"Tsai J.J.","year":"1994","journal-title":"Kaohsiung J Med Sci"},{"issue":"11","key":"e_1_2_7_24_2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1099\/0022-1317-74-11-2385","article-title":"Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection","volume":"74","author":"Okamoto H.","year":"1993","journal-title":"J Gen Virol"},{"key":"e_1_2_7_25_2","first-page":"1","article-title":"NIH Consensus Statement on Management of Hepatitis C: 2002","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00590.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01196.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22319"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JCM.38.8.2933-2939.2000","article-title":"Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test","volume":"38","author":"Yu M.L.","year":"2000","journal-title":"J Clin Microbiol"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087271"},{"key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa\u20102b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem S.","year":"2004","journal-title":"J Hepatol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_7_35_2","first-page":"210","article-title":"Clinical significance and interpretation of antinuclear antibodies","volume":"147","author":"White R.H.","year":"1987","journal-title":"West J Med"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260229"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01035.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1420431"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00705.x"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X11002543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X11002543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2011.10.031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.kjms.2011.10.031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2011.10.031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T06:27:24Z","timestamp":1694672844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.kjms.2011.10.031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1016\/j.kjms.2011.10.031"],"URL":"https:\/\/doi.org\/10.1016\/j.kjms.2011.10.031","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"value":"1607-551X","type":"print"},{"value":"2410-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}